An observational study in Colon Cancer, sponsored by Skane University Hospital. Recruiting at 1 site in Sweden. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Skane University Hospital · Observational
P) patients with acute obstructive colon cancer I) resection or bridge to surgery with stent or stoma C) emergency procedure O ) morbidity and mortality within 30 days, 90 day mortality and 3 \& 5 years overall survival
The aim of this prospective observational study is to evaluate primary resection for malignant obstruction of the colon compared to only decompression as first intervention regarding postoperative outcomes. We hypothesize that patients with malignant obstruction benefit from avoidance of emergency cancer resection, by a two-stage procedure, with decompression by a stoma or stent as first intervention, leading to decreased short-term morbidity and mortality and improved long-term oncological outcome.
2,457 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 227 across 555 observational studies indexed under Colonic Neoplasms.
Browse Colonic Neoplasms studies →Skane University Hospital is the lead sponsor of 73 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Prospective observational cohort study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who present with obstruction due to colon cancer with a need for urgent intervention who are treated with acute resection.
Patients who present with obstruction due to colon cancer with a need for urgent intervention who are treated with bridge to surgery i.e. either stent or stoma and resection later on.
Procedure: Bridge to Surgery (stent or stoma)
The study is an observational study and patients will not be randomized. Resection is defined as upfront surgical resection, Bridge to Surgery as a two stage procedure.
Number of patients with 30-day severe morbidity
Clavien-Dindo \>3 within 30 days postop
Time frame: 30 days
Overall survival after 3 years
survival unspecified
Time frame: 3 years
Number of patients with 30 day mortality
death within 30 days
Time frame: 30 days
Overall survival after 5 years
survival unspecified
Time frame: 5 years
Number of patients with 90 day mortality
death within 90 days
Time frame: 90 days
Number of patients with locally radical resections
resections regarded as R0
Time frame: 90 days
Number of examined mesenteric lymph nodes
lymph nodes examined by pathologist
Time frame: 90 days
Proportion of patients receiving neoadjuvant or adjuvant treatment
patients receiveing chemotherapy
Time frame: 1 year
Proportion of patients with stomas after 3 years
patients with bowel continuity without stome
Time frame: 3 years
Recurrence rate after 3 after years
relapse within 3 years
Time frame: 3 years
Disease-free survival after 3 years
survival without disease relapse after 3 years
Time frame: 3 years
Proportion of patients not being subjected to resection of initially decompressed
patients not proceeding to resection
Time frame: 90 days
bridging interval
interval between stenting or stoma and resection
Time frame: 90 days
Number of stent complications (perforations, migration, bleeding, success rate etc)
complications in stent group
Time frame: 90 days
Number of stoma complications
complications in stoma group
Time frame: 90 days
Morbidity and survival and impact of tumour location
30 day morbidity and mortality depending on tumour location i.e. right or left colon
Time frame: 5 years
Number of laparoscopic resections
numbers of laparoscopic vs open resections
Time frame: 90 days
Number of primary anastomosis
number of primary anastomosis in the Bridge to Surgery vs up front resection group
Time frame: 90 days
Number of stomas after resection and type of stoma
number of stomas in Bridge to Surgery vs up front resection group
Time frame: 90 days
total hospital stay in days
days in hospital in Bridge to Surgery vs up front resection
Time frame: 90 days
colorectal surgeon performing resectional surgery
qualified colorectal surgeon, general surgeon or resident performing resectional surgery
Time frame: 90 days
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Supporting information: Study protocol
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Skane University Hospital